AshwagandhavsLemon Balm

Ashwagandha's withanolide compounds (withaferin A, withanolide A, withanone) modulate the hypothalamic-pituitary-adrenal (HPA) axis, reducing corticotropin-releasing hormone (CRH) and adrenocorticotropic hormone (ACTH) signaling, thereby lowering cortisol production by 25-30% in stressed individuals. It acts as a GABA-A receptor positive allosteric modulator at the benzodiazepine site, producing anxiolytic effects without sedation. Ashwagandha inhibits acetylcholinesterase (AChE), raising acetylcholine levels in the hippocampus and cortex. The withanolides have anti-inflammatory properties via inhibition of NF-κB and COX-2, and antioxidant effects that reduce neuroinflammation and oxidative stress. It may support neurogenesis through upregulation of BDNF and its receptor TrkB, and modulation of the PI3K/Akt pathway.

Lemon balm inhibits GABA-transaminase (GABA-T), the enzyme that converts GABA to succinic semialdehyde in the GABA shunt, increasing GABA availability in synaptic terminals and producing anxiolytic effects via GABA-A (alpha2, alpha3 subunits) and GABA-B receptors. Rosmarinic acid provides antioxidant effects via Nrf2 activation and anti-inflammatory effects through COX-2 and NF-kB inhibition. Lemon balm inhibits acetylcholinesterase (AChE) at the catalytic site, mildly increasing acetylcholine in the hippocampus and cortex — explaining cognitive enhancement at moderate doses via muscarinic M1 and nicotinic receptor activation. At higher doses, GABAergic effects dominate, producing sedation useful for sleep. Additional mechanisms may include 5-HT2A antagonism and muscimol-like GABA-A modulation from trace constituents.